Literature DB >> 4608406

Critique of experimental trials of therapy in multiple sclerosis.

G A Schumacher.   

Abstract

Entities:  

Mesh:

Year:  1974        PMID: 4608406     DOI: 10.1212/wnl.24.11.1010

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

1.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

2.  Hyperbaric oxygen in multiple sclerosis.

Authors:  D J Perrins
Journal:  J R Soc Med       Date:  1987-04       Impact factor: 5.344

3.  Hyperbaric oxygen in multiple sclerosis.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-08

4.  Hyperbaric oxygen in chronic progressive multiple sclerosis: visual evoked potentials and clinical effects.

Authors:  J Neiman; B Y Nilsson; P O Barr; D J Perrins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

5.  Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis.

Authors:  O R Hommers; K J Lamers; P Reekers
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

6.  Modifications of the cerebrospinal fluid IgG concentrations in patients with multiple sclerosis treated with intrathecal steroids.

Authors:  A R Massaro
Journal:  J Neurol       Date:  1978-12-22       Impact factor: 4.849

7.  Failure of basic protein therapy for multiple sclerosis.

Authors:  R E Gonsette; P Delmotte; L Demonty
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849

Review 8.  Multiple sclerosis.

Authors:  C M Poser
Journal:  Med Clin North Am       Date:  1979-07       Impact factor: 5.456

9.  Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness.

Authors:  U Patzold; P Pocklington
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

10.  Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

Authors:  R E Gonsette; L Demonty; P Delmotte
Journal:  J Neurol       Date:  1977-02-17       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.